All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

28

Reset

28 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • IBI362Phase 38 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea

  • EfimosferminBOS-580Phase 37 trials

    GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic

  • Saroglitazar MagnesiumPhase 35 trials

    Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis

  • ALN-CIDEBPhase 34 trials

    Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD

  • HTD1801Berberine UrsodeoxycholatePhase 34 trials

    Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes

  • PemvidutidePhase 34 trials

    Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)

  • EfruxiferminPhase 33 trials

    Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH

  • pegargiminaseADI-PEG 20Phase 33 trials

    Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma

  • PegozaferminBIO89-100Phase 33 trials

    Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia

  • HSK31679Phase 32 trials

    Haisco Pharmaceutical Group Co., Ltd. · MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis), Non-Alcoholic Steatohepatitis (NASH)

  • IVA337LanifibranorPhase 31 trial

    Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis

  • HRS-4729Phase 23 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity

  • ARO-INHBEPhase 22 trials

    Arrowhead Pharmaceuticals · Metabolic Dysfunction-Associated Steatohepatitis, Obesity

  • ECC4703Phase 22 trials

    Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis

  • EfinopegdutideMK-6024, HM12525APhase 22 trials

    Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic

  • HU6Phase 22 trials

    Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver

  • NNC0194-0499Phase 22 trials

    Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis

  • AZD2693Phase 21 trial

    AstraZeneca · Nonalcoholic Steatohepatitis

  • BI 770371Phase 21 trial

    Boehringer Ingelheim · Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)

  • ECC0509Phase 21 trial

    Eccogene · Metabolic Dysfunction-associated Steatohepatitis

  • efocipegtrutideHM15211Phase 21 trial

    Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis

  • QL2401Phase 21 trial

    Qilu Pharmaceutical Co., Ltd. · Metabolic Dysfunction-associated Steatohepatitis (MASH)

  • SNP-610Phase 21 trial

    Sinew Pharma Inc. · NASH - Nonalcoholic Steatohepatitis

  • TGM-312-SC01Phase 21 trial

    Tangram Therapeutics Plc · Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis

  • TQA2225AP025Phase 21 trial

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Non-alcoholic Steatohepatitis

  • ZSP1601Phase 21 trial

    Guangdong Raynovent Biotech Co., Ltd · Nonalcoholic Steatohepatitis (NASH)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.